Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures
- PMID: 12114433
Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures
Abstract
Purpose: The FEZ1/LZTS1 (FEZ1) gene, located on chromosome 8p22 (8p22), was identified recently as a candidate tumor suppressor gene. Because loss of heterozygosity at 8p21-22 is a frequent event in lung cancers, we studied FEZ1 alteration in short-term cultures of resected lung cancer tumors and cell lines.
Experimental design: We examined FEZ1 expression in 17 non-small cell lung cancer (NSCLC), 19 small cell lung cancer (SCLC) cell lines, and 6 pairs of short-term cultures of resected NSCLCs and accompanying nonmalignant bronchial cells (NBECs) by reverse transcription-PCR and Western blotting. To investigate the mechanism for silencing, cells were cultured with 5-aza-2'-deoxycytidine or trichostatin A. We screened for genomic mutations by PCR-single-strand conformational polymorphism.
Results: Thirteen of 17 NSCLC (76%) and 3 of 19 SCLC (16%) of cell lines showed absent expression (P = 0.001). Of the paired NSCLC-NBEC cultures, 3 of 6 showed loss of expression in tumor cell cultures. In the cell lines retaining expression, the amplicon products in SCLCs were more intense than those of NSCLCs and NBECs. Expression of FEZ1 was not restored by 5-aza-2'-deoxycytidine and trichostatin A. Although FEZ1 expression was moderately correlated with loss of heterozygosity of specific microsatellite makers at 8p21-22 in NSCLC cell lines, it was strongly correlated to D8S261 and LPL loci in SCLC cell lines. No mutation was found within cording region of FEZ1 by PCR-single-strand conformational polymorphism.
Conclusions: We found differential FEZ1 expression in NSCLC and SCLC cell lines, and the absent expression in 3 of 6 short-term cultures of NSCLC tumors. FEZ1 may be related to tumorigenesis of lung cancer.
Similar articles
-
Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas.Int J Oncol. 2003 Aug;23(2):297-302. Int J Oncol. 2003. PMID: 12851677
-
Fez1/lzts1 alterations in gastric carcinoma.Clin Cancer Res. 2001 Jun;7(6):1546-52. Clin Cancer Res. 2001. PMID: 11410489
-
Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.Cancer Res. 2005 Feb 15;65(4):1207-12. doi: 10.1158/0008-5472.CAN-04-3461. Cancer Res. 2005. PMID: 15735004
-
Molecular genetics of small cell lung carcinoma.Semin Oncol. 2001 Apr;28(2 Suppl 4):3-13. Semin Oncol. 2001. PMID: 11479891 Review.
-
Novel schizophrenia risk factor pathways regulate FEZ1 to advance oligodendroglia development.Transl Psychiatry. 2017 Dec 18;7(12):1293. doi: 10.1038/s41398-017-0028-z. Transl Psychiatry. 2017. PMID: 29249816 Free PMC article. Review.
Cited by
-
Tumor microenvironment-related multigene prognostic prediction model for breast cancer.Aging (Albany NY). 2022 Jan 20;14(2):845-868. doi: 10.18632/aging.203845. Epub 2022 Jan 20. Aging (Albany NY). 2022. PMID: 35060926 Free PMC article.
-
MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1.Nat Commun. 2013;4:1877. doi: 10.1038/ncomms2876. Nat Commun. 2013. PMID: 23695671
-
LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.Oncotarget. 2014 Feb 28;5(4):970-7. doi: 10.18632/oncotarget.1630. Oncotarget. 2014. PMID: 24448468 Free PMC article.
-
Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development.Cancer Cell. 2007 Mar;11(3):275-89. doi: 10.1016/j.ccr.2007.01.014. Cancer Cell. 2007. PMID: 17349584 Free PMC article.
-
Aberrant methylation of SPARC in human lung cancers.Br J Cancer. 2005 Mar 14;92(5):942-8. doi: 10.1038/sj.bjc.6602376. Br J Cancer. 2005. Retraction in: Br J Cancer. 2013 Feb 19;108(3):744. doi: 10.1038/bjc.2013.68. PMID: 15756262 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical